LRMR Stock — Larimar Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (“CPP”) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (“FXN”), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”).

Source: 10-K FY2025 via SEC EDGAR

Share price

$2.39

Market cap

$248.3M

Cash

$156.3M

Enterprise value

$92.0M

Balance sheet

Cash	$156.3M
Debt	$0.0M
Net cash	$156.3M
Enterprise value	$92.0M
Basic shares	103.9M shares
Fully diluted shares	121.2M shares
Fully diluted market cap	$289.6M
Cash per share	$1.50
Quarterly burn	$44.0M
Cash runway	3.5 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

103.9M

Pre-funded warrants

—

Options

11.1M

RSUs

1.2M

Warrants

—

Converts

0.0M

Conv preferred

5.0M

ESPP reserve

—

FDSO

121.2M

Cap table as of 2026-08-02.

Price history

Loading LRMR daily closes…

Loading price history…

Next catalyst

nomlabofusp · Est. Nov 7, 2026 · half midpoint · guided Now

Recently reported

nomlabofusp Positive · 2026-06-29

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	nomlabofusp nomlabofusp open-label study in Friedreich's ataxia	Not disclosed	Friedreich's ataxia	H2 2026
Feb 12 - Mar 26 in 14 wks	CTI-1601	Phase 2	Friedreich Ataxia	—
Aug 12 - Sep 23 in 34 mo	Nomlabofusp	Phase 3	Friedreich Ataxia; Friedreich's Ataxia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Nomlabofusp

Phase 2 · Active Modality: fusion protein

Target FXN (frataxin)

Partnerships Indiana University (exclusive license, 2016; Wake Forest license expired Dec 2025)

Indications

Friedreich's ataxia (Phase 2)

Catalysts

— second half of 2026

Status note Subcutaneously administered recombinant FXN-delivery fusion protein (CPP platform). Breakthrough Therapy Designation granted Feb 2026; rolling BLA submitted (first module Jun 2026). Confirmatory global Phase 3 study with first dosing expected mid-2026.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Nomlabofusp
Lead indication	Friedreich Ataxia
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07778836	Phase 3	Recruiting	Sponsor	LRMR	—	Friedreich Ataxia; Friedreich's Ataxia	H2 2026 Est. Nov 7, 2026 · half midpoint
NCT06447025	Phase 2	Recruiting	Sponsor	LRMR	—	Friedreich Ataxia	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Larimar Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Deerfield Management	35,606,974	no change	1.13%	2026-08-14
RTW Investments	2,565,999	+1,065,999	0.07%	2026-08-14
DAFNA Capital	2,008,164	-21,000	1.17%	2026-08-14
Sphera Biotech	926,004	+926,004	0.40%	2026-08-14
ADAR1 Capital Management	272,745	+220,000	0.04%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

LRMR — Larimar Therapeutics Inc. ☆